- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly plans 200 jobs at new $440M Ireland plant
February 27, 2012
IBJ Staff and Bloomberg NewsEli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork
in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
MoreDrugmakers singing same song: 2012 will be tough
February 2, 2012
Associated PressFor drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out
new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview
mirror any more.
MoreLilly eying deal with Turkish drug company
January 31, 2012
Bloomberg NewsEli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in
a deal that may value the Turkish drugmaker at $1 billion, sources say.
MoreLilly's quarterly profit tumbles, but tops Wall Street estimates
January 31, 2012
J.K. WallPatent expirations on Gemzar and Zyprexa contributed to the 27-percent earnings decline, but CEO John Lechleiter touted better-than-expected
sales of other products.
MoreLilly's ex-partner wins FDA approval for diabetes drug
January 29, 2012
Bloomberg NewsAmylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly
and Co. co-developed the drug, but ended its partnership with Amylin last year.
MoreEli Lilly unit plans to buy feed-enzyme maker
January 24, 2012
Associated PressDrugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products
that improve poultry, egg and meat production.
MoreLechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MoreLilly's Zyprexa pact with health providers wins approval
January 12, 2012
Bloomberg NewsEli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper
marketing of the company's best-selling medication, Zyprexa, raised their costs.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreBoston lawsuit claims DES-breast cancer link
January 8, 2012
Associated PressFifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES
for millions of pregnant women from about 1938 to the early 1970s.
MoreLilly's 2012 earnings forecast misses analyst estimates
January 5, 2012
Bloomberg News, Associated PressIndianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a
wide margin, sending shares down.
MoreLilly challenging Biogen patent in London lawsuit
January 5, 2012
Bloomberg NewsEli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system
diseases.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MorePatent expirations up pressure on Lilly
December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into
the long-awaited zone of uncertainty that it calls “Years YZ.”
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MoreTakeda, Lilly may face thousands of suits over Actos claims
December 1, 2011
Bloomberg NewsTakeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over
allegations that their Actos diabetes drug causes bladder cancer.
MoreDrugmakers, pharmacists at odds
November 28, 2011
J.K. WallIndianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins,
leading CVS to kick Lilly’s insulins off its list of recommended drugs.
MoreLilly committed to China despite IP woes
November 21, 2011
J.K. WallIndianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth
in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S.
and European markets.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreLilly files suit over flea medication sales from Australia
November 11, 2011
Scott OlsonThe Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's
trademark by reselling it to U.S. consumers online.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreLilly, Bristol-Myers approved to market wider Erbitux use
November 7, 2011
Bloomberg NewsEli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage
head and neck tumors.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreLilly hid Zyprexa's diabetes risks, family’s lawyer argues
November 2, 2011
Bloomberg NewsEli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who
died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award
the family $40 million in compensatory damages.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
The Fringe! Plus, the simple fact that there are so many local faves in such close proximity to each other.
I remenber, watching the toll road, being built, through South Bend, when I was 10 years old. I believe, back then that it was estimated, that the toll road, would be paid for in 20 years and then it would be free. I am now 71, what happened? Since the power is in the people, by that, I mean that, we the people are in total control of everything. I, suggest that no one ever use the toll road again, let it go broke. We the people can control the price of everything, from groceries to gas, if we would just do it. If we don't pay the asking price, the sellers will lower the price and if we wait awhile, they will lower the price to what we accept as reasonable. I would like to know why a highway like interstate 94, is so well maintained, a much better highway, than the toll road, but has no tolls. I would also like to know why, a sitting governor, with a term limit, maximum of eight years, can lease, public property, for 75 years. Even though I have transponders in both of my trucks and will not be affected by the increase, I have been and will contine to avoid using the toll road. I make many trips from northern Indiana to Chicago, every year, and I prefer the better highway, I94!
Coming from her background,she should be used to those kinds of advances! Menard probably figured it was ok to tuck a buck!
I'm still waiting for the list of available, high quality apartments in the Village.
This criminal masquerading as a lawyer obviously has serious issues. He’s been proven by his own testimony to be a pathological liar and probably has a personality disorder as he seems to be constructing a reality around himself. He places no value on truth, honesty or loyalty as evidenced by what he has done to his clients and his own family. And by the demands and lies he has made in court, it is evident he feels entitled to do and say whatever suits his purpose and everyone else is expected to nod obediently and believe him because he is, after all, Bill Super Lawyer; or BS lawyer for short. This millionaire wanna-be no longer owns anything of value; he squandered it and put everything he had into foreclosure. He has no money, house, car, boat or vacation home left to show for what he earned or what he stole. He’s just another loser without morals who will be doing time. I’m certain all of his courtroom shenanigans are antagonizing his poor victims. As Lamar said, his behavior and claims in court have been outrageous. The judge needs to be more than concerned; he needs to be judicial and end this nonsense.